Zoetis (ZTS) News Today

Zoetis Inc. (NYSE: ZTS) showed relative strength as the broader market weakened, supported primarily by a new product approval and optimism ahead of its upcoming quarterly results. However, investors remain cautious because of softer U.S. pet-care demand and reduced guidance.

• Positive Sentiment: The FDA approved Convenia RTU, a single-dose injectable antibiotic for dogs. The product expands Zoetis’ companion-animal portfolio and could provide a new source of prescription revenue. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts and Zacks’ earnings indicators point to the possibility of a third-quarter earnings beat, which may be improving sentiment ahead of the report. Zoetis expected to beat earnings estimates
• Neutral Sentiment: Zacks Research upgraded Zoetis from “strong sell” to “hold.” The move reduces negative pressure but stops short of signaling a bullish outlook. Zacks Research stock recommendations
• Neutral Sentiment: A valuation-compression thesis argues that Zoetis may be inexpensive relative to animal-health peers IDEXX Laboratories and Elanco, while livestock and international sales have helped offset weakness in U.S. pet care. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain concerned that weaker U.S. pet-care demand and lower company guidance could limit a broader recovery, making the upcoming earnings report and outlook important catalysts.